Literature DB >> 9178653

Cardiac effects of isoliquiritigenin.

J W Wegener1, H Nawrath.   

Abstract

The effects of isoliquiritigenin on force of contraction (Fc), L-type Ca2+ current (I(Ca)) and intracellular Ca2+ concentration ([Ca2+]i) were investigated in rat ventricular heart muscle. Isoliquiritigenin increased Fc and I(Ca) and, after longer exposure times, resting tension and [Ca2+]i. The effect of isoliquiritigenin (100 microM) on I(Ca) was diminished by Rp-cAMPS (30 microM). 1H-[1,2,4]oxa- diazolo[4,3-a]quinoxalin-1-one (50 microM) did not influence the effects of isoliquiritigenin on Fc and I(Ca). The positive inotropic effects of isoprenaline and forskolin, but not of 3-isobutyl-1-methylxanthine, were potentiated by isoliquiritigenin (100 microM). In the presence of milrinone (10 microM), no further effects of isoliquiritigenin (100 microM) on Fc and I(Ca) were observed. It is suggested that the increase in Fc and I(Ca) by isoliquiritigenin is due to an accumulation of cyclic AMP. These effects are probably unrelated to an effect of the drug on soluble guanylyl cyclase, as reported for smooth muscle, but rather due to a direct inhibition of phosphodiesterase III activity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9178653     DOI: 10.1016/s0014-2999(97)00134-9

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

1.  Effects of nitric oxide donors on cardiac contractility in wild-type and myoglobin-deficient mice.

Authors:  J W Wegener; A Gödecke; J Schrader; H Nawrath
Journal:  Br J Pharmacol       Date:  2002-06       Impact factor: 8.739

Review 2.  The role of chalcones in suppression of NF-κB-mediated inflammation and cancer.

Authors:  Vivek R Yadav; Sahdeo Prasad; Bokyung Sung; Bharat B Aggarwal
Journal:  Int Immunopharmacol       Date:  2010-12-22       Impact factor: 4.932

3.  Protective effect of isoliquiritigenin against cerebral injury in septic mice via attenuation of NF-κB.

Authors:  Peng Zou; Hong-Ming Ji; Jian-Wei Zhao; Xin-Min Ding; Zi-Gang Zhen; Xuan Zhang; Xiao-Qi Nie; Li-Xiong Xue
Journal:  Inflammopharmacology       Date:  2018-06-26       Impact factor: 4.473

4.  Effects of isoliquiritigenin on ovarian antral follicle growth and steroidogenesis.

Authors:  Sharada Mahalingam; Liying Gao; Jacqueline Eisner; William Helferich; Jodi A Flaws
Journal:  Reprod Toxicol       Date:  2016-10-20       Impact factor: 3.143

5.  Effects of phosphodiesterase 3,4,5 inhibitors on hepatocyte cAMP levels, glycogenolysis, gluconeogenesis and susceptibility to a mitochondrial toxin.

Authors:  Mohammad Abdollahi; Tom S Chan; Vangala Subrahmanyam; Peter J O'Brien
Journal:  Mol Cell Biochem       Date:  2003-10       Impact factor: 3.396

6.  Cancer chemopreventive activity and metabolism of isoliquiritigenin, a compound found in licorice.

Authors:  Muriel Cuendet; Jian Guo; Yan Luo; Shaonong Chen; Carol P Oteham; Richard C Moon; Richard B van Breemen; Laura E Marler; John M Pezzuto
Journal:  Cancer Prev Res (Phila)       Date:  2010-01-12

7.  The inhibitory effect of Isoliquiritigenin on the proliferation of human arterial smooth muscle cell.

Authors:  Tianbao Chen; Shaoxiong Deng; Rong Lin
Journal:  BMC Pharmacol Toxicol       Date:  2017-07-17       Impact factor: 2.483

Review 8.  Emerging role of Garcinol, the antioxidant chalcone from Garcinia indica Choisy and its synthetic analogs.

Authors:  Subhash Padhye; Aamir Ahmad; Nikhil Oswal; Fazlul H Sarkar
Journal:  J Hematol Oncol       Date:  2009-09-02       Impact factor: 17.388

9.  Antimicrobial and antioxidative activities of bioactive constituents from Hydnophytum formicarum Jack.

Authors:  Supaluk Prachayasittikul; Prasit Buraparuangsang; Apilak Worachartcheewan; Chartchalerm Isarankura-Na-Ayudhya; Somsak Ruchirawat; Virapong Prachayasittikul
Journal:  Molecules       Date:  2008-04-18       Impact factor: 4.411

10.  The Effects of the Honey-Roasting Process on the Pharmacokinetics of the Six Active Compounds of Licorice.

Authors:  Yulong Zhang; Mengyue Wang; Jingyu Yang; Xiaobo Li
Journal:  Evid Based Complement Alternat Med       Date:  2018-06-21       Impact factor: 2.629

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.